| Title |
Metabolic consequences of acute and chronic empagliflozin administration in treatment-naive and metformin pretreated patients with type 2 diabetes
|
|---|---|
| Published in |
Diabetologia, December 2015
|
| DOI | 10.1007/s00125-015-3845-8 |
| Pubmed ID | |
| Authors |
Elza Muscelli, Brenno Astiarraga, Elisabetta Barsotti, Andrea Mari, Freimut Schliess, Leszek Nosek, Tim Heise, Uli C. Broedl, Hans-Juergen Woerle, Ele Ferrannini |
| Abstract |
Sodium glucose co-transporter 2 (SGLT2) inhibitors lower glycaemia by inducing glycosuria, but raise endogenous glucose production (EGP). Metformin lowers glycaemia mainly by suppressing EGP. We compared the effects of the SGLT2 inhibitor empagliflozin in treatment-naive (TN) and metformin pretreated (Met) patients with type 2 diabetes. A total of 32 TN and 34 patients on a stable dose of metformin, two subgroups of a study that we previously reported, received a mixed meal with double-tracer glucose administration and indirect calorimetry at baseline, after a single 25 mg dose of empagliflozin, and after 4 weeks of treatment with empagliflozin 25 mg/day. At baseline, compared with the TN group, the Met group had higher fasting glycaemia (9.1 ± 1.7 vs 8.2 ± 1.3 mmol/l), lower fasting and postmeal insulin secretion, lower beta cell glucose sensitivity (37 [18] vs 58 [43] pmol min(-1) m(-2) [mmol/l](-1), median [interquartile range]) and insulin:glucagon ratio, and higher fasting EGP (15.9 [4.3] vs 12.1 [2.7] μmol kgFFM (-1) min(-1)). Change from baseline in fasting EGP after single dose and 4 weeks of treatment with empagliflozin was similar in the Met and TN groups (19.6 [4.2] and 19.0 [2.3] in Met vs 16.2 [3.6] and 15.5 [3.2] μmol kgFFM (-1) min(-1) in TN for acute and chronic dosing, respectively). Beta cell glucose sensitivity increased less in Met than TN patients, whereas substrate utilisation shifted from carbohydrate to fat more in Met than TN patients. At baseline, Met patients with type 2 diabetes had more advanced disease than TN patients, featuring worse beta cell function and higher EGP. Empagliflozin induced similar glycosuria and metabolic and hormonal responses in Met and TN patients. ClinicalTrials.gov NCT01248364; European Union Clinical Trials Register 2010-018708-99. |
X Demographics
The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 25% |
| United Kingdom | 1 | 25% |
| Unknown | 2 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 4 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 55 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Russia | 1 | 2% |
| Unknown | 54 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 8 | 15% |
| Student > Bachelor | 8 | 15% |
| Researcher | 7 | 13% |
| Student > Ph. D. Student | 4 | 7% |
| Student > Doctoral Student | 3 | 5% |
| Other | 13 | 24% |
| Unknown | 12 | 22% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 22 | 40% |
| Pharmacology, Toxicology and Pharmaceutical Science | 8 | 15% |
| Biochemistry, Genetics and Molecular Biology | 4 | 7% |
| Agricultural and Biological Sciences | 4 | 7% |
| Business, Management and Accounting | 1 | 2% |
| Other | 3 | 5% |
| Unknown | 13 | 24% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 April 2016.
All research outputs
#13,224,317
of 22,849,304 outputs
Outputs from Diabetologia
#4,175
of 5,035 outputs
Outputs of similar age
#182,982
of 390,627 outputs
Outputs of similar age from Diabetologia
#43
of 70 outputs
Altmetric has tracked 22,849,304 research outputs across all sources so far. This one is in the 41st percentile – i.e., 41% of other outputs scored the same or lower than it.
So far Altmetric has tracked 5,035 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 22.7. This one is in the 16th percentile – i.e., 16% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 390,627 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 52% of its contemporaries.
We're also able to compare this research output to 70 others from the same source and published within six weeks on either side of this one. This one is in the 37th percentile – i.e., 37% of its contemporaries scored the same or lower than it.